Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 14/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487321 | 0.84 | USP30 (0.45) | FASN | |
| SCHEMBL16486306 | 0.82 | FASN (0.65) | FASNMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL17921558 | 0.81 | KDM4E (0.44) | FASNKMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL16486430 | 0.81 | KDM4E (0.44) | FASNKMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL16486438 | 0.79 | FASN (0.44) | FASNALDH1A1 | |
| SCHEMBL16486515 | 0.79 | L3MBTL1 (0.46) | FASNALDH1A1L3MBTL1 | |
| SCHEMBL16486893 | 0.77 | EGLN1 (0.43) | FASN | |
| SCHEMBL15717437 | 0.75 | FASN (0.44) | FASNAPPPAX8GAACYP1A2 | |
| SCHEMBL15717184 | 0.75 | FASN (0.47) | FASNAPPGAACYP1A2CYP3A4 | |
| SCHEMBL16512930 | 0.75 | CYP3A4 (0.44) | FASNAPPPAX8GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3033339-B1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | claimed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | claimed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | claimed |
| EP-3033339-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-22 | — | — | EP | claimed |
| WO-2015022038-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | WO | claimed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-10118919-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2018-11-06 | — | — | US | disclosed |
| EP-3033339-B1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| EP-3033339-B1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20180022738-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | disclosed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | disclosed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | disclosed |
| EP-3033339-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022038-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022738-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | FASN, FADS1, ACOX3 | FASN 1/4885APP 993/4885PAX8 4238/4885 |
| US-10118919-B2 | 3-substituted cyclopentylamine derivatives | FASN, FADS1, ACOX3 | FASN 1/4885APP 993/4885PAX8 4238/4885 |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | FASN 2790/4885APP 561/4885PAX8 3934/4885 |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | FASN, FADS1, ACOX3 | FASN 1/4885APP 993/4885PAX8 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.